News
CRMD
7.88
+0.38%
0.03
Oppenheimer Initiates Coverage of CorMedix at Outperform
NASDAQ · 5d ago
CorMedix Price Target Announced at $15.00/Share by Oppenheimer
Dow Jones · 5d ago
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15
Benzinga · 5d ago
Weekly Report: what happened at CRMD last week (0914-0918)?
Weekly Report · 09/21 09:28
Weekly Report: what happened at CRMD last week (0907-0911)?
Weekly Report · 09/14 09:30
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
NASDAQ · 09/07 13:55
Weekly Report: what happened at CRMD last week (0831-0904)?
Weekly Report · 09/07 09:28
CorMedix (CRMD) Upgraded to Buy: Here's Why
NASDAQ · 08/31 16:00
Weekly Report: what happened at CRMD last week (0824-0828)?
Weekly Report · 08/31 09:30
Weekly Report: what happened at CRMD last week (0817-0821)?
Weekly Report · 08/24 09:30
Cormedix Inc. Earnings Call Signals Strong Growth
TipRanks · 08/21 00:22
CorMedix: Durable Commercial Base, But 2027 Is The Real Test
Seeking Alpha · 08/18 09:23
Weekly Report: what happened at CRMD last week (0810-0814)?
Weekly Report · 08/17 09:31
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 08/14 15:36
RBC Capital Sticks to Their Buy Rating for Cormedix (CRMD)
TipRanks · 08/14 12:36
Buy Rating Reiterated on CRMD as Analyst Sees Undervalued Post-2027 Growth and Maintains $13 Price Target
TipRanks · 08/14 10:25
Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)
TipRanks · 08/13 17:30
CorMedix shares jump 15% after Q2 earnings beat
Seeking Alpha · 08/13 17:14
CorMedix Stock Jumps on Strong DefenCath Sales
Benzinga · 08/13 14:56
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday
Benzinga · 08/13 13:57
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.